San Diego, CA (PressExposure) March 05, 2012 -- An in-depth analysis of Trovagene, Inc., has described the molecular diagnostics company as being led by a triumvirate of "highly-experienced and respected leaders in biotechnology" whose patented technology platform could dramatically change the industry.
The assessment was detailed in a report published in February by BioMedReports on its website, http://www.biomedreports.com. The site describes itself as "the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence."
Trovagene (Pink Sheets: TROV.PK) stock doubled recently, the article said.
The piece called reader attention to "this intriguing diagnostics" company which brought together three successful figures in biotechnology -- Antonius Schuh, Gabriele Cerrone and Dr. Thomas A. Adams.
Schuh served as CEO of Sequenom from 2000 to 2005 and was appointed Trovagene CEO late last year, the article pointed out, and added that among his other achievements was the founding of AviaraDx, a molecular diagnostic innovator in oncology that was sold to bioMerieux in 2008.
Cerrone, founder of Trovagene, also was founder and chairman of FermaVir Pharmaceuticals, which was bought out in 2007 by Inhibitex, which later was acquired by Bristol-Myers Squibb, the article noted.
Adams, according to the article, founded Gen-Probe, now a leading molecular diagnostic product and services company, and also served in senior management positions with leading medical device and diagnostic companies. He serves as Trovagene's board chairman.
Trovagene believes it has a next-generation technology to screen for diseases using a patient's urine sample, the article states.
"Trovagene's patent-protected, new-generation molecular diagnostics platform could transform the molecular in-vitro diagnostics industry as it's known today," the article said.
The technology rests on the detection of trans-renal nucleic acids in urine, it said. Cell-free fragments of DNA that cross the kidney barrier can be detected in urine. These fragments are than used as genetic markers of disease, the story noted.
For further information, please contact:
The Promotion Factory
5 E. 19th St.,
New York, NY 10003